Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?

ESMO Open. 2019 May 9;4(2):e000480. doi: 10.1136/esmoopen-2018-000480. eCollection 2019.

Authors

Benedetta Pellegrino^{1

2}, Joaquin Mateo³, Violeta Serra¹, Judith Balmaña⁴

Affiliations

¹ Experimental Therapeutics Group, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain.
² Oncology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
³ Prostate Cancer Translational Research Group, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain.
⁴ High Risk and Cancer Prevention Group, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain.

No abstract available

Keywords: PARPi; breast cancer; homologous recombination deficiency; ovarian cancer; prostate cancer.

Publication types

Editorial